Cytokines affect resistance of human renal tumour cells to complement-mediated injury

Scandinavian Journal of Immunology

Volumn 57, Issue 6, 2003, Pages 591-599

  Blok, V T ^a   Gelderman, K A ^a   Tijsma, O H M ^a   Daha, M R ^a   Gorter, A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; C REACTIVE PROTEIN; CD59 ANTIGEN; COMPLEMENT; CYTOKINE; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; MEMBRANE COFACTOR PROTEIN; RENAL TUMOR ASSOCIATED ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ACTIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUMOR; LYSIS; MEASUREMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; ANTIGENS, NEOPLASM; BASE SEQUENCE; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-1; INTERLEUKIN-4; KIDNEY NEOPLASMS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0038717063     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01265.x     Document Type: Article

References (51)

1. Pittman K, Selby P. The management of renal cell carcinoma. Crit Rev Oncol Hematol 1994;16:181-200.
2. Young RC. Metastatic renal-cell carcinoma: What causes occasional dramatic regressions? N Engl J Med 1998;338:1305-6.
3. Hrouda D, Muir GH, Dalgleish AG. The role of immunotherapy for urological tumours. Br J Urol 1997;79:307-16.
4. Figlin RA. Renal cell carcinoma: Management of advanced disease. J Urol 1999;161:381-6.
5. Oosterwijk E, Bander NH, Divgi CR et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993;11:738-50.
6. Steffens MG, Boerman OC, Oosterwijk-Wakka JC et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529-37.
7. Grabmaier K, Vissers JLM, De Weijert MCA et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000;85:865-70.
8. Oosterwijk E, Ruiter DJ, Wakka JC et al. Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma. Am J Pathol 1986;123:301-9.
9. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994;12:1497-515.
10. Riethmuller G, Holz E, Schlimok G et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16 (5): 1788-94.
11. White CA, Weaver RL, Grillo-López AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001;52:125-45.
12. Vasey PA. Immunotherapy for renal carcinoma: theoretical basis and current standard of care. Br J Clin Pharmacol 2000;50:521-9.
13. Bjørge L, Vedeler CA, Ulvestad E, Matre R. Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol 1994;24:1597-603.
14. Yamakawa M, Yamada K, Tsuge T et al. Protection of thyroid cancer cells by complement-regulatory factors. Cancer 1994;73:2808-17.
15. Juhl H, Helmig F, Baltzer K, Kalthoff H, Henne Bruns D, Kremer B. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J Surg Oncol 1997;64:222-30.
16. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol 1996;61:201-83.
17. Morgan BP, Harris CL. Complement Regulatory Proteins, 1st edn. London: Academic Press, 1999.
18. Blok VT, Daha MR, Tijsma O et al. Bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 1998;160:3437-43.
19. Gelderman KA, Kuppen PJ, Bruin W, Fleuren GJ, Gorter A. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur J Immunol 2002;32:128-35.
20. Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogel CW. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiology 1997;197:444-59.
21. Oosterwijk E, Ruiter DJ, Hoedemaeker PhJ et al. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489-94.
22. Seelen MAJ, Brooimans RA, Van der Woude FJ, Van Es LA, Daha MR. IFN-gamma mediates stimulation of complement C4 biosynthesis in human proximal tubular epithelial cells. Kidney Int 1993;44:50-7.
23. Corver WE, Cornelisse CJ, Hermans J, Fleuren GJ. Limited loss of nine tumor-associated surface antigenic determinants after tryptic cell dissociation. Cytometry 1995;19:267-72.
24. Vogt RF Jr, Whitfield WE, Henderson LO, Hannon WH. Fluorescence intensity calibration for immunophenotyping by flow cytometry. Methods 2000;21:289-96.
25. Hazelbag S, Fleuren GJ, Baelde JJ, Schuuring E, Kenter GG, Gorter A. Cytokine profile of cervical cancer cells. Gynecol Oncol 2001;83:235-43.
26. Gorter A, Blok VT, Haasnoot WHB, Ensink NG, Daha MR, Fleuren GJ. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complemented-mediated tumor cell lysis. Lab Invest 1996;74:1039-49.
27. Holthöfer H, Miettinen A, Paasivuo R et al. Cellular origin and differentiation of renal carcinomas. A fluorescence microscopic study with kidney-specific antibodies, antiintermediate filament antibodies, and lectins. Lab Invest 1983;49:317-26.
28. Bjørge L, Skeie Jensen T, Ulvestad E, Vedeler CA, Matre R. The influence of tumour necrosis factor-α, interleukin-1β and interferon-gamma on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29. Scand J Immunol 1995;41:350-6.
29. Bjørge L, Jensen TS, Matre R. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother 1996;42:185-92.
30. Koch I, Depenbrock H, Danhauser-Riedl S, Rastetter JW, Hanauske A-R. Interleukin 1 modulates growth of human renal carcinoma cells in vitro. Br J Cancer 1995;71:794-800.
31. Moutabarrik A, Nakanishi I, Namiki M et al. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46 (MCP), CD55 (DAF), and CD59 on human vascular endothelial cells. Lymphokine Cytokine Res 1993;12:167-72.
32. Hillman GG, Puri RK, Kukuruga MA, Pontes JE, Haas GP. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-α) on human renal cell carcinoma. Clin Exp Immunol 1994;96:476-83.
33. Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 1993;91:88-93.
34. Tan J, Newton CA, Djeu JY et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 1996;56:3399-403.
35. Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A. Expression of transforming growth factor α in normal human adult kidney and enhanced expression of transforming growth factors α and β1 in renal cell carcinoma. Cancer Res 1989;49:6972-5.
36. Knoefel B, Nuske K, Steiner T et al. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-β1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 1997;17:95-102.
37. Nakagomi H, Pisa P, Pisa EK et al. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 1995;63:366-71.
38. Riemann D, Kehlen A, Langner J. Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular eptithelial cells by T cell-derived cytokines, such as IL-4 and IL-13. Clin Exp Immunol 1995;100:277-83.
39. Andoh A, Fujiyama Y, Sumiyoshi K, Sakumoto H, Okabe H, Bamba T. Tumour necrosis factor-α up-regulates decay-accelerating factor gene expression in human intestinal epithelial cells. Immunology 1997;90:358-63.
40. Wagstaff J, Baars JW, Wolbink G-J, Hoekman K, Eerenberg-Belmer AJM, Hack CE. Renal cell carcinoma and interleukin-2: a review. Eur J Cancer 1995;31A:401-8.
41. Yasumura S, Lin W, Weidmann E, Hebda P, Whiteside TL. Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2. Int J Cancer 1994;59:225-34.
42. Venneker GT, Vodegel RM, Okada N, Westethof W, Bos JD, Asghar SS. Relative contributions of decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 in the protection of melanocytes from homologous complement. Immunobiology 1998;198:476-84.
43. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 1998;113:173-82.
44. Pasch MC, Bos JD, Daha MR, Asghar SS. Transforming growth factor-β isoforms regulate the surface expression on membrane cofactor protein (CD46) and CD59 on human keratinocytes. Eur J Immunol 1999;29:100-8.
45. Varsano S, Rashkovsky L, Shapiro H, Radnay J. Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines. Am J Respir Cell Mol Biol 1998;19:522-9.
46. Blom DJR, Goslings WRO, De Waard-Siebinga I et al. Lack of effect of different cytokines on expression of membrane-bound regulators of complement activity on human uveal melanoma cells. J Interferon Cytokine Res 1997;17:695-700.
47. Andoh A, Fujiyama Y, Sumiyoshi K, Sakumoto H, Bamba T. Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells. Gastroenterology 1996;111:911-8.
48. Nasu J, Mizuno M, Uesu T et al. Cytokine-stimulated release of decay-accelerating factor (DAF; CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol 1998;113:379-85.
49. Bjørge L, Matre R. Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole. Scand J Immunol 1995;42:512-6.
50. Spiller OB, Criado-García O, De Córdoba SR, Morgan BP. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol 2000;121:234-41.
51. Zhanqi L, Smyth FE, Rennet C, Lee FT, Oosterwijk E, Scott AM. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cytotoxicity. Cancer Immunol Immunother 2002;51:171-7.